We therefore hypothesize that, following acute coronary syndrome, patients may lose the protective effects of adiponectin, potentially due to its involvement in OxLDL inhibition and the consequent reduction in macrophage transformation into foam cells (Figure 2). The gene discussed is ADIPOQ; the disease is acute coronary syndrome.